IN THE UNITED STATES PATENT AND TRADEMARK CONICE						PATENT
*			•		APP	<u>LICATION</u>
Inventor(s): ENGEL et al.			Group Art Ur Examiner:	Minnifield		1,45
	68,145			PM 217506	93 116 PH	
Series Code ↑ S	erial No. ↑	OIPA	•	M#	Client Ref	h.
Filed: June 6, 1995		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Appln. Title:	Oligopeptide Lyo	philisate	ල්ගි
Hon. Commissioner of Patents	ı	E 007 2	<u>ත</u>		الع	
Washington, D.C. 20231		OCT 2 6 2000	99		BECK	Mar
		V F	u'		ke.	T. Times
Sir:	IT/I ETTED	ANEWS OFFE	Date:	October 26, 2000	NON	1590
Filed: June 6, 1995 Hon. Commissioner of Patents Washington, D.C. 20231 Sir: REPLY/AMENDMENT/LETTER Date: October 26, 2000 This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto. FEE REQUIREMENTS FOR CLAIMS AS AMENDED						
This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject						
which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a						
signature thereto.						
FEE REQUIREMENTS FOR CLAIMS AS AMENDED						
Small Entity claim						
A. NOT made For B & C	Claims remaining after	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code
C. made herewith Separate Paper	amendment	previously paid for				Lg/Sm
D. made previously (Pat-256)						İ
	·			040/00	. 60	103/203
2. Total Effective Claims		**minus 0	0	x \$18/\$9 =	+ \$0 + \$0	103/203
3. Independent Claims		***minus 0	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters <u>proper</u> multipl				+ \$260/\$130 =	+ \$0	104/204
time (leave <u>blank</u> if this is a <u>reissue</u> ap 5. Original due Date: August 26, 2		NONE	auu	. ψ200/ψ100	_ Ψο	10 1/201
6. Petition is hereby made to extend			\$110/\$55 =	1	1 1 2	115/215
date to cover the date this response is			\$390/\$195 =	+ \$390		116/216
requisite fee is attached	s incu for wino	(3 mos)	\$890/\$445 =	,		117/217
(Usable only for ≤ 2mo.OA 4 mos) \$1390/\$695=						118/218 128/228
(Usable only for 30 day/1mo.OA 5 mos) \$1890/\$945=					a project	120,220
7. Enter any previous extension fee paid since above original due date and subtract - \$0						
8.1 Extension Fee Attached					+ \$390	5 4 5
9. If Terminal Disclaimer attached, add Rule 20(d) official fee					+ \$0	148/248
10. If iDS attached requires Official Fee,				+ \$240 =	+ \$0	126
or if Rule 97(d) Petitionadd + \$130				+ \$130 =		122
11. After-Final Request Fee per rules 129(a) and 17(r) + \$355/710 =					+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b) x \$710/355 ea =					+ \$0	149/249
13. Request for Continued Examination (RCE) + \$710/355=					+ \$0	1179/1279
14. Petition fee for					+ \$0	
15. TOTAL FEE ENCLOSED =					\$390	
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0". 17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.						
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.						
Our Deposit Account No. 03-3975) (Our Order No. 11468 217506						
C# M#						
CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be						
filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a						
duplicate copy of this sheet is attached.						
This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is Query: Is apple						
so, the Notice of Appeals Separate						
	Pillsbury Madison & Sutro LLP Intellectual Property Group					
1100 New York Avenue, NW	By Atty:		•	Reg. No.	36830	
Ninth Floor	• •		/ 4		-	
Washington, DC 20005-3918	Sig:	C 1. 4	hon_	Fax:	(202) 822-	0944

Tel: (202) 861-3000

Atty/Sec: ASH/maf

Tel:

(202) 861-3063



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION

ENGEL et al

08/468,145 Appln. No.

Filed: June 6, 1995

Group Art Unit: 1645

Examiner: N. Minnifield

OLIGOPEPTIDE LYOPHILISATE, THEIR PREPARATION AND USE Title:

October 26, 2000.

RESPONSE

Hon. Commissioner of Patents and Trademarks Washington, D C. 20231

Sir:

In response to the Office Action issued May 26, 2000 in the above-referenced application, please consider the following remarks.

10/27/2000 NROCHA1 00000043 08468145

01 FC:116

390.00 OP

REMARKS

Claims 20-23 are under examination. Reconsideration is requested.

Claims 20-23 stand rejected under 35 USC § 102(b) or (e) as being anticipated by Engel et al. (USP 5,663,145). This rejection is traversed for the following reasons.

First, Applicants submit that the '145 patent is not a printed publication more than one year prior to the date of the present application, and is therefore not a valid reference under 35 USC § 102(b). The '145 patent was filed on December 8, 1994 and issued on September 2, 1997. The present